184 related articles for article (PubMed ID: 27922588)
1. Does the addition of ezetimibe to statins reduce cardiovascular risk?
Araya FI; Grassi B
Medwave; 2016 Dec; 16(Suppl5):e6632. PubMed ID: 27922588
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
4. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
5. Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.
Wallach-Kildemoes H; Hansen EH
Eur J Clin Pharmacol; 2015 Oct; 71(10):1245-54. PubMed ID: 26227068
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Ma YB; Chan P; Zhang Y; Tomlinson B; Liu Z
Expert Opin Pharmacother; 2019 Jun; 20(8):917-928. PubMed ID: 30908086
[TBL] [Abstract][Full Text] [Related]
7. [FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)].
Scheen AJ
Rev Med Liege; 2016 Jan; 71(1):47-52. PubMed ID: 26983314
[TBL] [Abstract][Full Text] [Related]
8. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
9. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis.
Luo L; Yuan X; Huang W; Ren F; Zhu H; Zheng Y; Tang L
Intern Med J; 2015 May; 45(5):546-57. PubMed ID: 25644680
[TBL] [Abstract][Full Text] [Related]
10. Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes.
Fei Y; Guyatt GH; Alexander PE; El Dib R; Siemieniuk RAC; Vandvik PO; Nunnally ME; Gomaa H; Morgan RL; Agarwal A; Zhang Y; Bhatnagar N; Spencer FA
J Eval Clin Pract; 2018 Feb; 24(1):222-231. PubMed ID: 28090731
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
[TBL] [Abstract][Full Text] [Related]
12. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Araujo MB; Pacce MS
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
[TBL] [Abstract][Full Text] [Related]
13. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
Masana L; Pedro-Botet J; Civeira F
Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
[No Abstract] [Full Text] [Related]
14. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.
Mascitelli L; Pezzetta F; Goldstein MR
Arch Med Res; 2010 Nov; 41(8):649-50. PubMed ID: 21199735
[TBL] [Abstract][Full Text] [Related]
15. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
16. [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets].
Masana L; Plana N
Clin Investig Arterioscler; 2015; 27(3):138-43. PubMed ID: 25865752
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Statins and Ezetimibe in Guideline-Focused Management.
Bin Abdulhak AA; Robinson JG
Cardiol Clin; 2018 May; 36(2):221-223. PubMed ID: 29609751
[TBL] [Abstract][Full Text] [Related]
19. Improve-it: Full disclosures?
Nicot P; Guerbaai RA; Ennezat PV
Int J Cardiol; 2015 Dec; 201():380-1. PubMed ID: 26310982
[No Abstract] [Full Text] [Related]
20. Statin and ezetimibe combination therapy in cardiovascular disease.
Dembowski E; Davidson MH
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
